Loading
Adding the brain-penetrant HER2 pill tucatinib to trastuzumab and capecitabine lengthened survival in heavily pretreated HER2-positive metastatic breast cancer, and uniquely the trial included patients with active brain metastases, who also benefited.
Phase 3 placebo-controlled trial of 612 patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab and T-DM1, randomised 2:1 to tucatinib or placebo with trastuzumab and capecitabine; nearly half had brain metastases, including untreated or progressing lesions.
Overall survival at two years was 44.9 percent with tucatinib against 26.6 percent with placebo (hazard ratio 0.66); progression-free survival among patients with brain metastases at one year was 24.9 versus 0 percent.
Tucatinib-based therapy is the standard for HER2-positive disease with active brain metastases and a standard later-line option overall; it was the first trial to enrol progressing brain metastases and show a systemic drug helps them.
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
Shares Tucatinib, Trastuzumab, Capecitabine.
Shares HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib.
Shares Tucatinib, Trastuzumab, Capecitabine.
Shares Tucatinib, Trastuzumab.
Shares Tucatinib, Trastuzumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/